Zydus Lifesciences gets USFDA nod for generic drug to treat chest pain

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market Nitroglycerin Sublingual tablets, used to treat chest pain, in the American market.

The company has received approval from the US Food and Drug Administration (USFDA) for the drug in strengths of 0.3 mg, 0.4 mg and 0.6 mg, Zydus Lifesciences said in a statement.

Nitroglycerin Sublingual tablets belong to a class of drugs known as nitrates and are used to relieve chest pain (angina) in people who have a certain heart condition (coronary artery disease).

Angina occurs when the heart muscle is not getting enough blood.

The medication works by relaxing and widening blood vessels, so that blood can flow more easily to the heart, the drug firm stated.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The Zydus group now has 329 approvals and has so far filed over 400 abbreviated new drug approvals (ANDAs) since it commenced the filing process in 2003-04.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor